Minimal Vitrectomy Surgery for Epiretinal Membrane

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Jun 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new surgical approach called Minimal Vitrectomy Surgery (MVS) for patients with a condition known as idiopathic epiretinal membrane (ERM). This condition can lead to blurry vision due to a thin layer of tissue that grows on the retina, the part of the eye responsible for seeing. The trial compares MVS to the standard vitrectomy surgery to see which method better improves eyesight and manages cataract development over a year.

To participate in the trial, you need to be at least 18 years old and have been diagnosed with ERM through a thorough eye examination and specialized imaging. You should also have clear vision in your eye and be willing to provide consent for the study. However, if you’ve had cataract surgery before or have other serious eye conditions, you may not qualify. If you join the trial, you can expect to receive either the new surgery or the traditional method, with regular check-ups to monitor your progress and eye health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years.
• • 2. Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
• • 3. Clear ocular media allowing adequate fundus imaging.
• • 4. Phakic eye.
• • 5. Ability and willingness to provide written informed consent.
• Exclusion Criteria:
• • 1. Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
• • 2. Systemic conditions preventing safe surgery or follow-up.
• • 3. History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.